Coverage cuts for obesity drugs
- Insurers have cut coverage for leading GLP‑1 obesity medications, forcing many patients to change treatments or seek alternatives. (npr.org) - From 2025 to 2026, about 12 million people lost coverage for Wegovy and 12 million lost coverage for Zepbound. (npr.org) - Analysts say demand may hold despite a delayed Medicare pilot, and Amazon rolled out an integrated obesity care program tying One Medical to Amazon Pharmacy. (usnews.com) (indexbox.io)
Health plans are covering fewer obesity drugs, even as demand for Wegovy and Zepbound keeps climbing. (wskg.org) From 2025 to 2026, about 12 million people lost commercial coverage for Wegovy and another 12 million lost coverage for Zepbound, according to GoodRx research cited by NPR. GoodRx said more than 41 million people now lack commercial coverage for Wegovy and more than 109 million lack it for Zepbound. (wskg.org) (goodrx.com) Even when plans still cover these drugs, access is usually not simple. GoodRx said more than 88% of people with coverage for weight-loss uses still face extra hurdles such as prior authorization or step therapy, which requires trying another drug first. (goodrx.com) These medicines are used for obesity treatment, but insurers often treat that benefit as optional because employer plans and commercial insurers can decide whether to include anti-obesity drugs on their formularies. Wegovy’s Food and Drug Administration label also includes weight loss and cardiovascular risk reduction uses, which can shape coverage rules but does not guarantee payment. (accessdata.fda.gov) The coverage pullback is colliding with a market that is still expanding. Reuters reported on April 22 that analysts do not expect a delayed Medicare pilot to dent near-term demand for obesity drugs, after the Centers for Medicare & Medicaid Services postponed the program because insurers were reluctant to participate. (usnews.com) Drugmakers and retailers are building around that gap. Amazon’s One Medical launched a nationwide GLP-1 management program on April 21 that ties obesity treatment to primary care, virtual follow-ups, and Amazon Pharmacy fulfillment. (fiercehealthcare.com) Manufacturers are also leaning harder on cash-pay channels. Novo Nordisk says eligible commercially insured patients can pay as little as $25 a month for Wegovy, while its self-pay offers start at $149 for some doses and rise later in 2026 depending on strength. (wegovy.com) For patients, the result is a moving target: stay on the same drug and pay more, switch drugs to match a new formulary, or move outside insurance into savings cards, direct-pay programs, and pharmacy-linked care. The medical demand did not disappear; the bill is shifting. (wskg.org) (goodrx.com)
